5 days ago · In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type-2 inflammation or other allergic …

5 days ago · In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic …

Feb 18, 2006 · In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type-2 inflammation or other …

2 days ago · Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a …

Sep 11, 2005 · These positive pivotal results for bullous pemphigoid add to an immense body of scientific evidence that underscores the important role IL4 and IL13 play in driving diseases …

5 days ago · Investor Relations Mark Hudson Tel: +1 914-847-3482 [email protected] Investor Relations Thomas Kudsk Larsen Tel: +44 7545 513 …

4 days ago · Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease …

Sep 27, 2024 · In July 2024, Sanofi and Regeneron announced that the European Medicines Agency approved Dupixent as an add-on maintenance treatment for adults with uncontrolled …

Sep 11, 2024 · --Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent ® pivotal trial in bullous pemphigoid met the primary and all key secondary endpoints evaluating …

4 days ago · Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid …